The T and B cell response to SARS-CoV2 infection remains poorly understood. Some studies suggest an overaggressive immune response leading to immunopathology (51) whereas others suggest T cell exhaustion or dysfunction (12–14). Autopsies revealed high virus levels in the respiratory tract and other tissues (52), suggesting ineffective immune responses. Nevertheless, non-hospitalized subjects who recovered from COVID-19 had evidence of virus-specific T cell memory (53). SARS-CoV2-specific antibodies are also found in convalescent subjects and patients are currently being treated with convalescent plasma therapy (30, 54). However, COVID-19 ICU patients have SARS-CoV2-specific antibodies (30), raising the question of why patients with these antibody responses are not controlling disease. In general, these studies report on single patients or small cohorts and comprehensive deep immune profiling of a large number of COVID-19 hospitalized patients is limiting. Such knowledge would address the critical question of whether there is a common profile of immune dysfunction in critically ill patients. Such data would also help guide testing of therapeutics to enhance, inhibit, or otherwise tailor the immune response in COVID-19 patients.